Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer  by Di Maio, Massimo et al.
1830 Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012
Introduction: The TORCH (Tarceva or Chemotherapy) trial ran-
domized patients with advanced non–small-cell lung cancer to first-
line erlotinib followed by second-line cisplatin/gemcitabine versus. 
standard inverse sequence. The trial, designed to test noninferiority 
in overall survival, was stopped at interim analysis because of infe-
rior survival in the experimental arm. Quality of life (QoL), a sec-
ondary outcome, is reported here.
Methods: QoL was assessed at baseline and every 3 weeks during 
first-line, using European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire - Core 30 and QLQ–lung can-
cer specific module (LC13). Mean changes from baseline within arms 
were reported. QoL response and time-to-deterioration of QoL using 
a competing-risk approach were compared between treatment arms.
Results: Six hundred and thirty patients (83%) completed baseline 
questionnaires. Compliance was affected by differential treatment 
efficacy, but was similar between arms for patients without progres-
sion or death. Significant differences in QoL responses were observed 
favoring chemotherapy for pain, sleeping, dyspnea, diarrhea, and 
favoring erlotinib for vomiting, constipation, sore mouth, and alo-
pecia. In the small subset of patients with EGFR-mutated tumors, 
all selected items (global QoL, physical functioning, cough, dyspnea 
and pain) improved, whereas worsening or no change was observed 
in wild-type patients. Improvement was particularly evident in the 
first-line erlotinib arm as for global QoL and physical functioning.
Conclusions: QoL was impacted by differential toxicity and efficacy 
between arms. Functional domains and global QoL did not differ, 
although some symptoms were better controlled with chemotherapy 
in unselected non–small-cell lung cancer patients.
Key Words: Advanced non–small-cell lung cancer, Randomized 
trial, First-line treatment, Erlotinib, Chemotherapy, Health-related 
quality of life, EGFR.
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Lung cancer remains a leading global cause of cancer mor-tality and morbidity.1 Most patients present with advanced 
disease, and modest gains in survival, symptom control, and 
health-related quality of life (QoL) are attained with chemo-
therapy,2 and with second- or third-line erlotinib in unselected 
advanced non–small-cell lung cancer (NSCLC) patients after 
chemotherapy failure.3,4 Therefore patients’ preferences 
could be strongly affected by differences in toxicity profiles 
and convenience between parenteral chemotherapy and oral 
erlotinib.5–7 The TORCH (Tarceva or Chemotherapy) ran-
domized phase III trial tested noninferiority in overall sur-
vival with first-line erlotinib, followed by second-line doublet 
chemotherapy (cisplatin/gemcitabine), compared with the 
current inverse standard of first-line chemotherapy followed 
after progression by erlotinib, in unselected patients with 
advanced NSCLC.8 We hypothesized that survival outcomes 
could be similar, but that advantages in terms of toxicity, con-
venience, and quality of life could also be expected with first-
line erlotinib, even in an unselected NSCLC population. The 
study was prematurely stopped at the first interim analysis 
when inferiority of the experimental arm was demonstrated.8
In this article, we report results of QoL analyses during 
first-line treatment (cisplatin/gemcitabine versus erlotinib) in 
the TORCH trial, and an exploratory analysis of QoL differ-
ences between the two first-line strategies in the subgroup of 
patients with known EGFR mutation status.
PATIENTS AND METHODS
The TORCH trial (ClinicalTrials.gov number 
NCT00349219) was designed and conducted by the National 
Cancer Institute, Napoli, Italy, with collaborating centers in 
Italy and Canada. National Cancer Institute, Napoli, held 
and analyzed the data. Assessment of QoL during first-line 
treatment was a preplanned secondary outcome of this trial.
Study Population
Eligible patients had a confirmed pathologic diagnosis 
of advanced NSCLC (stage IV or IIIB with malignant pleural 
effusion or supraclavicular nodes), had Eastern Cooperative 
Oncology Group performance status 0 or 1, were aged less 
than 70 years (Canadian institutions did not apply age restric-
tion), and were suitable for first-line cisplatin-based doublet 
chemotherapy. Details of trial eligibility and conduct are pub-
lished elsewhere.8 Study conduct was approved by the research 
ethics boards of all participating institutions, and all patients 
provided written informed consent to participate.
Study Procedures
Consenting patients completed baseline assessments 
including QoL evaluation, and were then randomized in a 1:1 
ratio to either first-line erlotinib or first-line chemotherapy 
(cisplatin/gemcitabine). Patients randomized to the experi-
mental arm received erlotinib (150 mg/day) orally until dis-
ease progression or the development of unacceptable toxicity. 
Patients randomized to the standard arm received cisplatin 
(80 mg/m2 intravenously day 1) plus gemcitabine (1200 mg/
m2 intravenously days 1 and 8) every 3 weeks for a maximum 
of six cycles or until progression or unacceptable toxicity.
QoL Assessment
QoL assessment was mandatory for all study partici-
pants, but was limited to first-line treatment. This was to avoid 
expected selection bias of patients entering second-line ther-
apy, given the unknown differential impact of first-line therapy 
in the two treatment arms.
The European Organization for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire - Core 30 
(QLQ-C30) questionnaire9 and the lung cancer specific module 
(EORTC QLQ-LC13)10 were used to evaluate QoL at baseline 
and every 3 weeks in both arms (corresponding to end of cycles 
1, 2, 3, 4, 5, and 6 in the standard arm).
The EORTC QLQ-C309 is a 30-item questionnaire com-
posed of five multi-item functional subscales (physical, role, 
emotional, social, and cognitive functioning), three multi-item 
symptom scales (fatigue, pain, and emesis), a global health 
status subscale, and six single items to assess financial impact 
and symptoms such as dyspnea, sleep disturbance, appetite, 
diarrhea, and constipation, during the previous week. The 
EORTC QLQ-LC13 consists of 13 single items that evaluate 
specific symptoms of lung cancer.10 Both questionnaires are 
designed to be completed by the patient. Scores for multi-
item scales are calculated by deriving the mean raw scores 
of single items and transforming them linearly into scales 
ranging from 0 to 10011. For single items, only linear trans-
formation is performed. For the five functional subscales, 
(physical, role, emotional, cognitive, and social functioning) 
and global health status, higher values represent better func-
tion. For symptom scales, higher values represent greater 
severity of symptoms (i.e., worse).
Baseline questionnaires had to be completed before the 
first treatment administration. Subsequent questionnaires were 
completed at weeks 3, 6, 9, 12, 15, and 18. In the event of delays 
in chemotherapy administration, questionnaires were accepted 
if completed at least 14 days after the previous administration of 
chemotherapy and before the subsequent chemotherapy cycle.
QoL Analysis
QoL missing data patterns were reported according to 
the National Cancer Institute of Canada Clinical Trials Group 
QoL framework.12 Missing data fractions were reported under 
different scenarios: (1) rate of patients completing baseline 
assessments and the assessments at designated time points over 
the total number of patients eligible and entered into the trial; 
(2) rate of patients completing assessments at designated time 
points while on study over the total number completing assess-
ment at baseline; and (3) rate of patients completing assessments 
at designated time points over the number of patients still on 
study, who were expected to complete questionnaires at each of 
those time points (excluding those who progressed or were dead 
at that time point).
For each domain or symptom, mean changes within 
arms from baseline to the six planned time points were 
reported to provide a complete picture of QoL behavior. 
A positive value represents an improvement in functional 
scales, and a worsening in symptom scales. Only patients 
with available values at baseline and at each time point were 
included in the analysis.
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Two main QoL outcomes were compared between arms: 
(1) best QoL response and (2) time-to-deterioration of QoL. 
For best response, the first three questionnaires (3, 6, and 9 
weeks) were evaluated; for time-to-deterioration, all available 
questionnaires were evaluated. Because of the exploratory 
nature of the QoL analysis, adjustment for multiple item com-
parisons was not performed.
Best QoL response from baseline was derived for each 
domain or symptom as follows: a change score of at least 10 
points from baseline was defined as clinically relevant, as sug-
gested by Osoba et al.13; patients were considered improved if 
they reported a score of 10 points or more better than baseline 
at any time, and were considered worsened if they reported a 
score 10 or more points worse than baseline (without improve-
ment). Patients whose scores changed less than 10 points from 
baseline were considered stable. Only patients who had com-
pleted the baseline and at least one follow-up questionnaire 
within 9 weeks of treatment were included. An exact linear 
rank test was used to test whether the two study arms had 
the same underlying multinomial distribution of the ordered 
QoL response (Cytel Studio 9.0. 2010 Cytel Software Corp., 
Cambridge, MA).
Time-to-deterioration was defined as the time from 
randomization to QoL deterioration, using progression or 
death as competing events, that prevented the occurrence of 
QoL assessment. In the competing-risk approach,14 the dif-
ferent types of events are not considered independent, and 
subjects who experienced progression or death before docu-
mented QoL deterioration were not censored at the time of 
progression/death. Accordingly, cumulative incidence func-
tions, defined as the probability of deteriorating by the time t, 
were estimated for each domain and for each arm. Treatments 
were compared with the Gray method.15 Deterioration of QoL 
was defined as a worsening of 10 or more points from base-
line at any time during QoL assessment, irrespective of any 
improvement.
Analyses were repeated in the subgroup of patients with 
known EGFR mutation status for selected items that reflect 
disease-related effects (global QoL, physical functioning, 
cough, dyspnea, and pain). EGFR mutation analysis was per-
formed retrospectively on all available tumor samples.
RESULTS
Seven hundred and sixty patients were accrued in the 
TORCH trial, 612 from Italy and 148 from Canada (Fig. 1); 
630 completed baseline questionnaires, 315 (83%) in each 
arm (Fig. 1 and Fig. 2A). Patients with and without baseline 
QoL questionnaires were similar, with minor imbalances 
380 patients 
randomized to experimental arm
373 patients started 1st line erlotinib
7 patients did not start 1st line erlotinib
5 pts: refusal
1 pt: early death
1 pt: protocol violation
380 patients 
randomized to standard arm
371 patients started 1st line Cis + Gem
9 patients did not start 1st line Cis + Gem
5 pts: refusal
1 pt: early death
3 pts: protocol violation
760 patients
65 patients without valid 
baseline QoL
60 pts: did not complete 
baseline QoL
5 pts: completed baseline 
65 patients without valid 
baseline QoL
54 pts: did not complete 
baseline QoL
11 pts: completed baseline 
315 patients with valid baseline QoL questionnaire
Efficacy population (patients completing subsequent QoL out of 
those with valid baseline QoL):
• 232 pts with valid QoL at week 3   (cycle 1)
• 209 pts with valid QoL at week 6   (cycle 2)
• 164 pts with valid QoL at week 9   (cycle 3)
• 124 pts with valid QoL at week 12 (cycle 4)
• 109 pts with valid QoL at week 15 (cycle 5)
• 80 pts with valid QoL at week 18 (cycle 6)
Patients with baseline QoL and at least 1 valid questionnaire in the 
first 3 assessments (eligible for best response analysis): 257
315 patients with valid baseline QoL questionnaire
Efficacy population (patients completing subsequent QoL out of 
those with valid baseline QoL):
• 245 pts with valid QoL at week 3
• 191 pts with valid QoL at week 6
• 141 pts with valid QoL at week 9
• 88 pts with valid QoL at week 12
• 72 pts with valid QoL at week 15
• 65 pts with valid QoL at week 18
Patients with baseline QoL and at least 1 valid questionnaire in the 
first 3 assessments (eligible for best response analysis): 266
QoL after treatment start QoL after treatment start
FIGURE 1.  Flow-chart of TORCH study patients for QoL analysis. QoL, Quality of Life. 
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by country, smoking status, and EGFR mutation status 
(Table 1). Baseline characteristics of patients included 
in QoL analyses were well balanced between study arms 
(Table 2). Thirty-five percent of the patients were women, 
22% never smokers, and 56% had adenocarcinoma his-
tology. For all QoL items, baseline values were similar 
between arms. EGFR mutation status was available for 275 
patients (36.2%). Of these, 39 had tumors with activating 
EGFR mutations, 36 of whom were eligible for QoL analy-
sis. Baseline characteristics did not differ between patients 
with or without EGFR assessment.8
Compliance with QoL questionnaire completion sig-
nificantly decreased cycle after cycle, as expected in this 
poor-prognosis advanced-disease setting. In addition, com-
pliance was significantly impacted by differing disease pro-
gression and survival rates between the two study arms. At 3, 
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FIGURE 2. A, Rate of patients 
completing each Quality of Life 
assessment over the total number of 
patients entered into the trial B, over 
the total number completing assess-
ment at baseline and C, over the 
number of patients without progres-
sion or death at each of those time 
points. Blue bars, cisplatin + gem-
citabine; yellow bars, erlotinib.
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TABLE 1.  Baseline Characteristics of Patients With and 
Without Baseline Quality of Life Questionnaire
All Patients
Patients  
With  
Baseline QoL  
(n = 630)
Patients  
Without 
Baseline QoL 
(n = 130)
Country n (%)
Italy 493 (78%) 119 (92%)
Canada 137 (22%) 11 (8%)
Sex n (%)
Male 412 (65%) 92 (71%)
Female 218 (35%) 38 (29%)
Age (yr) n (%)
<70 592 (94%) 130 (100%)
>70 (only Canada) 38 (6%) 0
Ethnicity n (%)
East Asian 22 (3%) 2 (2%)
Other 608 (97%) 128 (98%)
Smoking status n (%)
Never smoker 141 (22%) 16 (12%)
Former or current smoker 489 (78%) 114 (88%)
ECOG performance status n (%)
0 319 (51%) 63 (48%)
1 311 (49%) 67 (52%)
Stage, n (%)
III B 70 (11%) 13 (10%)
IV 560 (89%) 117 (90%)
Histology, n (%)
Squamous, large cell, mixed undefined 278 (44%) 60 (46%)
Adenocarcinoma (incl. BAC) 352 (56%) 70 (54%)
EGFR mutation status n (%)
Not available 393 (62%) 92 (71%)
Available 237 (38%) 38 (29%)
Mutated 36 (15%) 3 (8%)
Wild type 201 (85%) 35 (92%)
QoL, Quality of Life questionnaire; BAC, bronchioloalveolar carcinoma; EGFR, 
epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group. 
TABLE 2.  (Continued)
Standard Arm  
(n = 315)
Experimental 
Arm (n = 315)
Age (yr), n (%)
<70 296 (94%) 296 (94%)
>70 19 (6%) 19 (6%)
Ethnicity, n (%)
East Asian 10 (3%) 12 (4%)
Other 305 (97%) 303 (96%)
Smoking status, n (%)
Never smoker 68 (22%) 73 (23%)
Former or current smoker 247 (78%) 242 (77%)
ECOG PS, n (%)
0 156 (50%) 163 (52%)
1 159 (50%) 152 (48%)
Stage, n (%)
III B 32 (10%) 38 (12%)
IV 283 (90%) 277 (88%)
Histology, n (%)
Squamous, large cell, mixed, undefined 136 (43%) 142 (45%)
Adenocarcinoma (incl. BAC) 179 (57%) 173 (55%)
EGFR mutation status, n (%)
Not available 195 198
Mutated 18 (15%) 18 (15%)
Wild type 102 (85%) 99 (85%)
Mean baseline value (SD)
Global QoL 56.7 (22.0) 58.0 (21.6)
Physical functioning 77.9 (20.5) 77.2 (20.0)
Role functioning 73.3 (27.8) 71.0 (28.5)
Emotional functioning 69.7 (22.5) 69.1 (22.4)
Cognitive functioning 88.6 (17.6) 88.3 (17.6)
Social functioning 79.9 (24.2) 81.1 (24.2)
Pain 27.2 (27.4) 24.7 (25.9)
Appetite 19.6 (27.0) 18.4 (25.8)
Constipation 14.3 (24.9) 14.4 (25.2)
Financial 11.1 (23.7) 15.0 (27.9)
Fatigue 30.6 (23.1) 30.7 (23.4)
Vomiting 7.3 (15.0) 7.3 (14.8)
Sleeping 25.7 (28.4) 24.2 (29.5)
Diarrhea 3.9 (12.3) 5.6 (14.8)
Dyspnea 24.4 (21.3) 25.9 (21.1)
Cough 32.9 (25.8) 35.8 (25.7)
Hemoptysis 3.6 (11.4) 4.3 (12.4)
Sore mouth 4.0 (14.5) 5.1 (14.7)
Swallowing 5.2 (15.0) 6.5 (18.0)
Neuropathy 7.8 (18.7) 8.0 (18.8)
Hair loss 4.2 (16.9) 5.1 (18.9)
Chest pain 14.2 (23.0) 13.6 (22.1)
Shoulder pain 16.0 (24.2) 17.7 (26.0)
Pain elsewhere 19.3 (28.8) 17.5 (25.8)
Analgesic use 47.9 (50.0) 42.7 (49.5)
ECOG, Eastern Cooperative Oncology Group; BAC, bronchioloalveolar 
 carcinoma; PS, performance status;QoL, quality of life; SD, standard deviation.
TABLE 2.  Baseline Characteristics and Quality of Life Values 
by Treatment Arm
Standard Arm  
(n = 315)
Experimental 
Arm (n = 315)
Country, n (%)
 Italy 246 (78%) 247 (78%)
 Canada 69 (22%) 68 (22%)
Sex, n (%)
Male 205 (65%) 207 (66%)
Female 110 (35%) 108 (34%)
(Continued)
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6, and 9 weeks, 74%, 66%, and 52% reported QoL scores in 
the chemotherapy arm, compared with 78%, 61%, and 45% 
respectively in the erlotinib arm (Fig. 2B). When limiting to 
patients who were progression-free, compliance was similar 
between arms (Fig. 2C). Because of chemotherapy treatment 
delays time lag of questionnaire completion from random-
ization was slightly larger in the standard arm than in the 
experimental one (Fig. 3).
Observed Changes in QoL from Baseline
Absolute mean differences in QoL items from baseline 
are depicted in Figure 4. But for emotional functioning func-
tional scales worsened during time for both arms (Fig. 4 A). 
Overall global QoL slightly improved with chemotherapy 
but slightly worsened in the experimental arm. Treatment-
related symptoms including constipation, fatigue, vomiting, 
neuropathy, and hair loss, all expected side effects of che-
motherapy, were worse in the standard arm. Diarrhea was 
worse in the erlotinib arm. Better control of cancer-related 
symptoms including pain, cough, and less use of analgesics 
was seen in patients receiving first-line chemotherapy (Fig. 
4 B and C).
In the subset of patients with EGFR-mutated tumors 
(Fig. 5), all selected items improved in EGFR-mutated 
patients whereas worsening or no change was observed in 
wild-type patients. Improvement was particularly evident in 
the first-line erlotinib arm as for global QoL and physical 
functioning.
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FIGURE 3.  Box-plot of time distribution of Quality of Life 
assessments compared with date of randomization, by treat-
ment arm. Line in the box, median value; box hinges, 25th to 
75th percentiles; ends of the segments, 10th to 90th percen-
tiles. Blue boxes: cisplatin/gemcitabine; yellow boxes: erlotinib.
FIGURE 4.  (Continued)
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FIGURE 4.  (Continued)  Mean differences in QoL scores. A, QLQ-C30 functioning scales (positive indicate improvement). B, 
QLQ-C30 symptoms scales (negative indicate improvement). C, QLQ-LC13 symptoms scales (negative indicate improvement). 
Blue bars, cisplatin/gemcitabine; yellow bars, erlotinib. QoL, Quality of Life.
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Analysis of QoL Response
QoL response results by treatment arms are reported in 
Table 3. Clinically relevant differences favoring chemotherapy 
were seen for pain, dyspnea, and sleep disorders. In the 
subgroup with EGFR-mutated tumors, similar responses were 
observed in the two arms, whereas chemotherapy overcame the 
experimental arm in subjects with EGFR wild type (Table 4).
Analysis of Time-to-Deterioration
Cumulative incidence functions of time-to-deterioration 
are reported in Figure 6. Statistically significant differences in 
time-to-deterioration were observed for diarrhea, which was 
worse with erlotinib, and vomiting, constipation, sore mouth, 
and hair loss, which were worse with chemotherapy.
Cumulative incidence functions of time-to-deterioration 
of selected items according to EGFR mutational status are 
reported in Figure 7.
DISCUSSION
The TORCH trial demonstrates that, in unselected 
patients with advanced NSCLC, significantly better response 
rates, progression-free and overall survival are observed with 
first-line chemotherapy compared with first-line erlotinib.8 
In the QoL analyses, however, the differences in global QoL 
scores between the arms were not significantly different. 
Impact of standard treatment in terms of disease symptoms 
control and side effects was consistent with the expected 
effect of platinum-based chemotherapy as first-line treat-
ment of advanced NSCLC, with mean changes from baseline 
showing a reduction in some symptoms (pain, cough) and an 
increase in several side effects (fatigue, vomiting, loss of appe-
tite, sore mouth, neuropathy, hair loss). Toxicity differences 
between the arms were clearly reflected in the QoL analyses, 
with more fatigue, alopecia, constipation, and vomiting seen 
with chemotherapy, and diarrhea with erlotinib, as expected. 
FIGURE 5.  Mean differences in selected QoL items 
in patients with EGFR mutated tumor and in patients 
with EGFR wild-type tumor. Blue bars, cisplatin/gem-
citabine; yellow bars, erlotinib. QoL, Quality of Life; 
EGFR, epidermal growth factor receptor. 
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Tumor-related symptom control was reflective of treatment 
efficacy, with better pain and dyspnea scores in the standard 
arm (chemotherapy). Compliance was slightly less in the 
experimental arm over time, related to greater clinical dete-
rioration in the erlotinib arm compared with chemotherapy.
To compare QoL between treatment arms, we calculated 
the best QoL response (the proportion of patients with clini-
cally meaningful differences for each item), which is the pre-
ferred analysis for health-related QoL data from clinical trials, 
according to the National Cancer Institute of Canada Clinical 
TABLE 3.  Best Quality of Life Response by Treatment Arm
Domain/Item
Standard Arm (n = 266)a Experimental Arm (n = 257)a
p
Improved  
(%)
Stable  
(%)
Worse  
(%)
Improved  
(%)
Stable  
(%)
Worse  
(%)
Global QoL 93 (36) 76 (30) 86 (34) 81 (31) 77 (29) 105 (40) 0.11
Physical functioning 56 (22) 102 (40) 96 (38) 50 (19) 112 (43) 100 (38) 0.65
Role functioning 71 (28) 76 (30) 108 (42) 71 (27) 77 (29) 116 (44) 0.72
Emotional functioning 92 (36) 99 (39) 64 (25) 70 (27) 113 (43) 78 (30) 0.04
Cognitive functioning 57 (23) 102 (40) 94 (37) 49 (18) 123 (46) 93 (35) 0.84
Social functioning 58 (23) 89 (35) 108 (42) 64 (24) 88 (33) 111 (42) 0.83
Pain 104 (41) 82 (32) 68 (27) 79 (30) 84 (32) 101 (38) 0.002
Appetite 61 (24) 95 (37) 100 (39) 46 (17) 115 (43) 104 (39) 0.39
Constipation 44 (17) 120 (47) 92 (36) 56 (21) 163 (62) 46 (17) <0.0001
Financial 23 (9) 175 (68) 58 (23) 33 (13) 179 (69) 49 (19) 0.13
Fatigue 89 (35) 43 (17) 124 (48) 91 (35) 49 (19) 123 (47) 0.83
Vomiting 35 (14) 87 (34) 133 (52) 40 (15) 145 (55) 79 (30) <0.0001
Sleeping 88 (35) 95 (37) 72 (28) 63 (24) 104 (39) 99 (37) 0.005
Diarrhea 21 (8) 182 (71) 53 (21) 21 (8) 133 (50) 110 (42) <0.0001
Dyspnea 67 (27) 122 (49) 62 (25) 48 (18) 127 (48) 88 (33) 0.005
Cough 91 (36) 115 (45) 49 (19) 81 (31) 112 (42) 72 (27) 0.05
Hemoptysis 18 (7) 221 (87) 16 (6) 19 (7) 214 (81) 32 (12) 0.10
Sore mouth 10 (4) 175 (68) 71 (28) 21 (8) 185 (70) 59 (22) 0.05
Swallowing 19 (7) 192 (75) 45 (18) 29 (11) 192 (73) 43 (16) 0.30
Neuropathy 23 (9) 182 (72) 49 (19) 37 (14) 176 (67) 49 (19) 0.26
Hair loss 12 (5) 125 (49) 117 (46) 14 (5) 217 (82) 33 (12) <0.0001
Chest pain 56 (22) 154 (60) 45 (18) 50 (19) 164 (62) 50 (19) 0.41
Shoulder pain 52 (21) 149 (59) 50 (20) 49 (19) 164 (63) 46 (18) 0.99
Pain elsewhere 60 (24) 129 (51) 62 (25) 57 (22) 126 (48) 77 (30) 0.27
Analgesic use 31 (13) 174 (70) 42 (17) 28 (11) 189 (73) 42 (16) 0.85
a According to Osoba et al.13 based on patients with at least one questionnaire at 3, 6, or 9 weeks after baseline.
Number and row percentage are reported for each item and within each arm; small changes in the total number can depend on missing responses in each item.
QoL, quality of life.
TABLE 4.  Quality of Life Response*a by Treatment Arm, by EGFR Mutational Status
Domain/item
EGFR Mutated (n=31)b EGFR Wild Type (n = 165)b
Standard Arm (n=15) Experimental Arm (n=16) Standard Arm (n = 82) Experimental Arm (n = 83)
Improved  
(%)
Stable 
(%)
Worse 
(%)
Improved  
(%)
Stable 
(%)
Worse 
(%)
Improved  
(%)
Stable 
(%)
Worse  
(%)
Improved 
(%)
Stable 
(%)
Worse 
(%)
Global QoL 6 (40) 5 (33) 4 (27) 8 (50) 4 (25) 4 (25) 28(35) 23 (28) 30 (37) 23 (28) 16 (20) 42 (52)
Physical functioning 5 (33) 6 (40) 4 (27) 8 (50) 3 (19) 5 (31) 19 (23) 29 (35) 34 (41) 10 (12) 29 (35) 43 (52)
Pain 7 (47) 5 (33) 3 (20) 9 (56) 4 (25) 3 (19) 31 (38) 20 (25) 30 (37) 20 (24) 25 (30) 38 (46)
Dyspnea 6 (40) 6 (40) 3 (20) 6 (38) 7 (44) 3 (19) 23 (29) 32 (41) 23 (29) 14 (17) 37 (45) 31 (38)
Cough 7 (47) 5 (33) 3 (20) 7 (44) 5 (31) 4 (25) 32 (40) 29 (36) 20 (25) 27 (33) 33 (40) 23 (28)
aAccording to Osoba et al.13 based on patients with at least one questionnaire at 3, 6, or 9 weeks after baseline.
bNumber and row percentage are reported for each item and within each arm; small changes in the total number can depend on missing responses in each item.
QoL, quality of life; EGFR, epidermal growth factor receptor. 
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Trials Group.12 In addition, we hypothesized that time-to-dete-
rioration analysis, including time to symptom worsening as 
defined by QoL response parameters, or disease progression 
or death, would better reflect the clinical differences between 
arms. However, despite the poor clinical outcomes in the 
experimental arm, we did not find a significant difference in 
time to global QoL or disease-related symptom deterioration.
On the basis of these results, the QoL analyses in this 
trial were reflective of differing treatment toxicity profiles, 
and able to capture greater symptom improvement in the 
chemotherapy arm. However, the analyses of global QoL 
do not reflect the significant differences in efficacy between 
arms, as would have been expected. It is unclear whether 
this is related to the measures used. The EORTC QLQ-C30 
and LC13 may be better instruments to capture treatment 
toxicity and elements of lung cancer symptom control. Or, 
despite evidence that systemic therapy improves QoL despite 
treatment toxicity,16 the impact of toxicity may overshadow 
potential QoL benefit in the standard arm.
The difference in QoL compliance, affected by differing 
disease progression and survival rates between study arms, 
reverberates differently on the two outcomes. It should not 
affect best QoL response, because it is very unlikely that 
patients progressed could subsequently experience clinical 
improvement in one or more items of QoL questionnaire. 
Conversely, it could affect time-to-deterioration, and for this 
reason we used the competing-risk approach, to speculate 
whether there would be differences between arms once the 
effect of competing events that prevent the outcome of interest 
is removed.
After initiation of the TORCH trial, several randomized 
trials have been reported comparing first-line EGFR tyrosine 
kinase inhibitor (gefitinib or erlotinib) with platinum-based 
chemotherapy in patients selected (by subgroup analysis17,18 or 
as inclusion criteria)19–22 for the presence of EGFR activating 
mutations. In the first of these trials, Mok et al.17 compared 
first-line carboplatin plus paclitaxel versus gefitinib in good 
performance status patients with lung adenocarcinoma and a 
light- or never-smoking history. In the subset analysis of patients 
with somatic EGFR activating mutations, better response 
rates and progression-free survival were seen in those treated 
with first-line gefitinib compared with chemotherapy. QoL 
scores were also better with gefitinib in the mutation-positive 
subgroup, compared with scores for those treated with first-
line chemotherapy. A clinically relevant improvement in global 
QoL was observed in 70% of EGFR mutation-positive patients 
FIGURE 6.  (Continued)  Cumulative incidence functions of time-to-deterioration for QoL items. A, QLQ-C30 functioning 
scales. B, QLQ-C30 symptoms scales. C, QLQ–lung cancer specific module (LC13) symptoms scales. Blue curves, cisplatin/gem-
citabine; yellow curves, erlotinib. QoL, Quality of Life.
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treated with gefitinib, compared with 45% of patients receiving 
chemotherapy (odds ratio 3.01, 95% confidence interval 1.79–
5.07, p < 0.0001). A significant interaction with EGFR mutation 
status was also demonstrated in the Trial Outcome Index,23 
which combines scores on physical well-being, functional well-
being, and lung cancer subscale of the Functional Assessment of 
Cancer Therapy-Lung instrument—and in the analysis of items 
related to lung cancer symptoms. Of note, both in terms of global 
QoL and in terms of lung cancer symptoms, improvements 
with gefitinib were usually rapid. In the First-SIGNAL trial, 
comparing chemotherapy to gefitinib in never smokers with 
lung adenocarcinoma, quality of life was assessed by the same 
measures used in TORCH, the EORTC QLQ-C30 and LC-1318. 
Gefitinib was associated with significantly better physical 
role and social function, compared with standard first-line 
chemotherapy. As for lung cancer symptoms, in the subgroup 
of patients with EGFR mutation positive tumors, gefitinib 
was associated with a better outcome in terms of hemoptysis, 
dysphagia, and pain compared with chemotherapy treatment.
In the TORCH trial, EGFR mutation status was known 
in only one third of the patients. With the low prevalence of 
EGFR mutations in Western patients, the absolute number of 
mutation-positive cases is low although well balanced between 
treatment arms. Mean differences from baseline in global QoL 
clearly show a differential impact of treatment, with erlotinib 
producing a consistent improvement of global QoL at all time 
points in mutation-positive cases, and a consistent deteriora-
tion of global QoL at all time points in wild-type cases. A 
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FIGURE 7.  Cumulative incidence functions of time-
to-deterioration for selected QoL items in patients 
with EGFR mutated tumor and in patients with EGFR 
wild-type tumor. Blue curves, cisplatin/gemcitabine; 
yellow curves, erlotinib. QoL, Quality of Life; EGFR, 
epidermal growth factor receptor.
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similar effect is seen for erlotinib also in physical function-
ing and in the three symptoms analyzed (cough, dyspnea, and 
pain). For patients with wild-type tumors, administration of 
erlotinib was associated with a worse outcome compared with 
chemotherapy in all items studied. Interestingly, there was 
a better symptom control in EGFR-mutated patients, com-
pared with wild-type cases, also for those assigned to che-
motherapy. Thus, our subanalyses confirm existing evidence 
that for EGFR wild-type patients, first-line erlotinib produces 
inferior clinical efficacy and inferior quality of life outcomes 
compared with chemotherapy, despite a more favorable toxic-
ity profile. Similarly, patients with EGFR mutation-positive 
tumors derive dramatic clinical and QoL benefit from first-
line EGFR tyrosine kinase inhibitor treatment, but also derive 
good clinical efficacy from chemotherapy, also reflected in 
favorable symptom-control scores.
First-line treatment with an EGFR tyrosine kinase 
inhibitor (gefitinib or erlotinib) in patients with EGFR muta-
tion-positive advanced NSCLC has become standard world-
wide.17–22 For those with EGFR wild type or unknown EGFR 
genotype, chemotherapy remains the first-line standard. QoL 
analyses, including those from the TORCH trial, support this 
treatment algorithm. In unselected patients with advanced 
NSCLC, QoL scores reflect not only treatment toxicity, but 
also better symptom control with chemotherapy.
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